Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia

Peter F Buckley, Jeffrey M. Goldstein, Robin A. Emsley

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

With the notable exception of clozapine, there is at present insufficient information on the efficacy of atypical antipsychotic medications in patients with poorly responsive schizophrenia. The present study reports on the efficacy and tolerability of quetiapine and haloperidol in patients with schizophrenia who showed no response to treatment with fluphenazine. This study is a post hoc subanalysis of an 8-week, double-blind study of patients receiving quetiapine 600 mg/day or haloperidol 20 mg/day. The proportion of patients classified as "Clinical Global Impression responders" (defined as Clinical Global Impression Severity of Illness score of ≤3 at study end) was greater in the quetiapine group compared with the haloperidol group (51% vs. 25%; P=0.023). Overall, quetiapine was well tolerated with less extrapyramidal side-effects and reduction in prolactin when compared to haloperidol. Weight gain was modest but more apparent in quetiapine-treated patients. Quetiapine is an appropriate treatment choice in patients who do not respond to prior antipsychotic treatment.

Original languageEnglish (US)
Pages (from-to)143-150
Number of pages8
JournalSchizophrenia Research
Volume66
Issue number2-3
DOIs
StatePublished - Feb 1 2004

Fingerprint

Schizophrenia
Haloperidol
Antipsychotic Agents
Fluphenazine
Clozapine
Double-Blind Method
Prolactin
Weight Gain
Quetiapine Fumarate
Therapeutics

Keywords

  • Antipsychotic
  • Haloperidol
  • Quetiapine
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. / Buckley, Peter F; Goldstein, Jeffrey M.; Emsley, Robin A.

In: Schizophrenia Research, Vol. 66, No. 2-3, 01.02.2004, p. 143-150.

Research output: Contribution to journalArticle

Buckley, Peter F ; Goldstein, Jeffrey M. ; Emsley, Robin A. / Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. In: Schizophrenia Research. 2004 ; Vol. 66, No. 2-3. pp. 143-150.
@article{4855916bef6c448e896e21702e9a5f99,
title = "Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia",
abstract = "With the notable exception of clozapine, there is at present insufficient information on the efficacy of atypical antipsychotic medications in patients with poorly responsive schizophrenia. The present study reports on the efficacy and tolerability of quetiapine and haloperidol in patients with schizophrenia who showed no response to treatment with fluphenazine. This study is a post hoc subanalysis of an 8-week, double-blind study of patients receiving quetiapine 600 mg/day or haloperidol 20 mg/day. The proportion of patients classified as {"}Clinical Global Impression responders{"} (defined as Clinical Global Impression Severity of Illness score of ≤3 at study end) was greater in the quetiapine group compared with the haloperidol group (51{\%} vs. 25{\%}; P=0.023). Overall, quetiapine was well tolerated with less extrapyramidal side-effects and reduction in prolactin when compared to haloperidol. Weight gain was modest but more apparent in quetiapine-treated patients. Quetiapine is an appropriate treatment choice in patients who do not respond to prior antipsychotic treatment.",
keywords = "Antipsychotic, Haloperidol, Quetiapine, Schizophrenia",
author = "Buckley, {Peter F} and Goldstein, {Jeffrey M.} and Emsley, {Robin A.}",
year = "2004",
month = "2",
day = "1",
doi = "10.1016/j.schres.2003.06.001",
language = "English (US)",
volume = "66",
pages = "143--150",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia

AU - Buckley, Peter F

AU - Goldstein, Jeffrey M.

AU - Emsley, Robin A.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - With the notable exception of clozapine, there is at present insufficient information on the efficacy of atypical antipsychotic medications in patients with poorly responsive schizophrenia. The present study reports on the efficacy and tolerability of quetiapine and haloperidol in patients with schizophrenia who showed no response to treatment with fluphenazine. This study is a post hoc subanalysis of an 8-week, double-blind study of patients receiving quetiapine 600 mg/day or haloperidol 20 mg/day. The proportion of patients classified as "Clinical Global Impression responders" (defined as Clinical Global Impression Severity of Illness score of ≤3 at study end) was greater in the quetiapine group compared with the haloperidol group (51% vs. 25%; P=0.023). Overall, quetiapine was well tolerated with less extrapyramidal side-effects and reduction in prolactin when compared to haloperidol. Weight gain was modest but more apparent in quetiapine-treated patients. Quetiapine is an appropriate treatment choice in patients who do not respond to prior antipsychotic treatment.

AB - With the notable exception of clozapine, there is at present insufficient information on the efficacy of atypical antipsychotic medications in patients with poorly responsive schizophrenia. The present study reports on the efficacy and tolerability of quetiapine and haloperidol in patients with schizophrenia who showed no response to treatment with fluphenazine. This study is a post hoc subanalysis of an 8-week, double-blind study of patients receiving quetiapine 600 mg/day or haloperidol 20 mg/day. The proportion of patients classified as "Clinical Global Impression responders" (defined as Clinical Global Impression Severity of Illness score of ≤3 at study end) was greater in the quetiapine group compared with the haloperidol group (51% vs. 25%; P=0.023). Overall, quetiapine was well tolerated with less extrapyramidal side-effects and reduction in prolactin when compared to haloperidol. Weight gain was modest but more apparent in quetiapine-treated patients. Quetiapine is an appropriate treatment choice in patients who do not respond to prior antipsychotic treatment.

KW - Antipsychotic

KW - Haloperidol

KW - Quetiapine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0347991819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347991819&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2003.06.001

DO - 10.1016/j.schres.2003.06.001

M3 - Article

C2 - 15061246

AN - SCOPUS:0347991819

VL - 66

SP - 143

EP - 150

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 2-3

ER -